Shares of Eli Lilly and Co LLY have lost almost 10 percent since the beginning of the year. However, they have managed to recuperate almost 10 percent since their mid-March lows.
Related Link: Here's How Crowdsourced Ratings Can Beat The Market
Following the most recent surge, top raters at the Vetr community have decided to upgrade their rating on shares of Eli Lilly from 3.5 Stars (Buy) to 4.5 Stars (Strong Buy) - out of a possible 5.0 Stars rating.
The new rating seems more aligned with the crowd’s target price of $88.67, which implies a 16 percent upside potential from current valuations. Also in line with the target and new rating from the top raters, the crowd has issued 77 percent bullish ratings.
Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
